Clinical Trial

Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
A multicenter Phase II, randomized, prospective, open-label Trial investigating the clinical impact on combining Specific Internal Radiotherapy (SIRT) with the PD1-L Inhibitor Durvalumab and the CTLA-4 Inhibitor Tremelimumab in patients with intrahepatic Biliary Tract Cancer
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2020-01-22; most recent amendment 2025-11-27.
Status change: Recruiting → Active, Not Recruiting 2025-11-27
Trial Details
NCT Number NCT04238637
Lead Sponsor Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Collaborators: AstraZeneca
Conditions Intrahepatic Cholangiocarcinoma
Enrollment 50 participants
Start Date 2019-11-01
Primary Completion 2026-08 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-05